Lancet Psychiatry
Fecha de publicación: October 20, 2020
DOI: https://doi.org/10.1016/S2215-0366(20)30339-4
Autores: Emma C Johnson, PhD , Ditte Demontis, PhD , Thorgeir E Thorgeirsson, PhD, Raymond K Walters, PhD, Renato Polimanti, PhD, Alexander S Hatoum, PhD, et al.
Background: Variation in liability to cannabis use disorder has a strong genetic component (estimated twin and family heritability about 50–70%) and is associated with negative outcomes, including increased risk of psychopathology. The aim of the study was to conduct a large genome-wide association study (GWAS) to identify novel genetic variants associated with cannabis use disorder.
